Angiotech Pharmaceuticals

ANP-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about ANP-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
July 4, 2006
Biotech stocks have not done well for quite awhile. Great company, but the market does not appreciate what they have in their pipeline. Big problem is that all their revenues are from stents via Boston who are having a number of recalls. Made a number of acquisitions in the last few years and expect they will start bearing fruit soon. Good management.
Show full opinionHide full opinion
Biotech stocks have not done well for quite awhile. Great company, but the market does not appreciate what they have in their pipeline. Big problem is that all their revenues are from stents via Boston who are having a number of recalls. Made a number of acquisitions in the last few years and expect they will start bearing fruit soon. Good management.
DON'T BUY
DON'T BUY
April 6, 2006
Coming out with other products is going to be their big task down the road. Hit and miss right now.
Show full opinionHide full opinion
Coming out with other products is going to be their big task down the road. Hit and miss right now.
PAST TOP PICK
PAST TOP PICK
March 28, 2006
(A Top Pick Nov 9/05. Up 4%.) When he picked these stocks, he was trying to play the Christmas bounce. All 3 failed to materialise. This is still in the basing period and has not broken out yet.
Show full opinionHide full opinion
(A Top Pick Nov 9/05. Up 4%.) When he picked these stocks, he was trying to play the Christmas bounce. All 3 failed to materialise. This is still in the basing period and has not broken out yet.
DON'T BUY
DON'T BUY
March 20, 2006
Manufactures coated stents. In competition with Johnson & Johnson (JNJ-N). A one trick pony. Boston Scientific (BSX-N) is a better way to play this.
Show full opinionHide full opinion
Manufactures coated stents. In competition with Johnson & Johnson (JNJ-N). A one trick pony. Boston Scientific (BSX-N) is a better way to play this.
VAGUE
VAGUE
February 14, 2006
He believes the sector is good, but has no position on this stock.
Show full opinionHide full opinion
He believes the sector is good, but has no position on this stock.
WATCH
WATCH
February 13, 2006
Just acquired American Medical Instruments. This is a very positive move which gives them the ability to grow. They'll have to do more of this to get the stock moving.
Show full opinionHide full opinion
Just acquired American Medical Instruments. This is a very positive move which gives them the ability to grow. They'll have to do more of this to get the stock moving.
DON'T BUY
DON'T BUY
December 5, 2005
Boston Scientific (BSX-N) is buying Guidant (GDT-N) which is a competitor of Angiotech. This is very negative for Angiotech. This company has been a one-hit wonder.
Show full opinionHide full opinion
Boston Scientific (BSX-N) is buying Guidant (GDT-N) which is a competitor of Angiotech. This is very negative for Angiotech. This company has been a one-hit wonder.
TOP PICK
TOP PICK
November 9, 2005
(A Top Pick July 4/05. Down 5%.) It is hard trying to read companies in the health care sector, but this one has had a long base with a lot of series of lows which seems to be that it is getting ready for a pop. All his picks are for a seasonal Santa Claus rally trade. If they move 20%, say thank you and get the heck out.
Show full opinionHide full opinion
(A Top Pick July 4/05. Down 5%.) It is hard trying to read companies in the health care sector, but this one has had a long base with a lot of series of lows which seems to be that it is getting ready for a pop. All his picks are for a seasonal Santa Claus rally trade. If they move 20%, say thank you and get the heck out.
BUY
BUY
September 29, 2005
Trading at around 13 X earnings which is cheap for a company that is growing. Market has given them a lot of credit for their coated stent, but is worried about competion and with them owning 75% of the market are not sure they can hold this. At a very cheap level now. Has bought it, and will continue to hold.
Show full opinionHide full opinion
Trading at around 13 X earnings which is cheap for a company that is growing. Market has given them a lot of credit for their coated stent, but is worried about competion and with them owning 75% of the market are not sure they can hold this. At a very cheap level now. Has bought it, and will continue to hold.
DON'T BUY
DON'T BUY
September 28, 2005
Using a 5 year chart as he wants to look at as it is coming back to multi-year support level. The trend is still bearish and there is no sign of it ending. Getting close to long term support and from that perspective it gets interesting. You need to see positive price action and some volume coming in.
Show full opinionHide full opinion
Using a 5 year chart as he wants to look at as it is coming back to multi-year support level. The trend is still bearish and there is no sign of it ending. Getting close to long term support and from that perspective it gets interesting. You need to see positive price action and some volume coming in.
BUY
BUY
September 19, 2005
Angiotech and Boston Scientific (BSX-N) are up against Johnson & Johnson (JNJ-N) which is like being in the ring with a heavyweight. Lost ground when they had their product recalled. Still a good company.
Show full opinionHide full opinion
Angiotech and Boston Scientific (BSX-N) are up against Johnson & Johnson (JNJ-N) which is like being in the ring with a heavyweight. Lost ground when they had their product recalled. Still a good company.
DON'T BUY
DON'T BUY
August 25, 2005
The medical device group is performing fairly well. The problem this company is having is that it is really a one product company which is a risk. Competition Johnson and Johnson (JNJ-N) has a product which is perceived to be safer so market share has dropped.
Show full opinionHide full opinion
The medical device group is performing fairly well. The problem this company is having is that it is really a one product company which is a risk. Competition Johnson and Johnson (JNJ-N) has a product which is perceived to be safer so market share has dropped.
WEAK BUY
WEAK BUY
August 22, 2005
Had some rough patches lately. Biggest claim to fame is licensing of their technology to Boston Scientific. They continue to be successful, the problem is, what do they do for an encore. Sales are set to decline. Have a good cash position and hopefully they will come up with a new product that will be successful. High risk and potentially high reward.
Show full opinionHide full opinion
Had some rough patches lately. Biggest claim to fame is licensing of their technology to Boston Scientific. They continue to be successful, the problem is, what do they do for an encore. Sales are set to decline. Have a good cash position and hopefully they will come up with a new product that will be successful. High risk and potentially high reward.
BUY
BUY
August 8, 2005
Continues to like this stock. Their stents, sold through Boston Scientific (BSX-N) is gaining market share over Johnson & Johnson (JNJ-N). A world class Canadian winner.
Show full opinionHide full opinion
Continues to like this stock. Their stents, sold through Boston Scientific (BSX-N) is gaining market share over Johnson & Johnson (JNJ-N). A world class Canadian winner.
TOP PICK
TOP PICK
July 4, 2005
The biotech sector of the TSX is absolutely the worst sector of the past couple of years. This one is a highly speculative pick. Can see a descending wedge on the chart which is a bullish sign. Watch for the breakout to the upside.
Show full opinionHide full opinion
The biotech sector of the TSX is absolutely the worst sector of the past couple of years. This one is a highly speculative pick. Can see a descending wedge on the chart which is a bullish sign. Watch for the breakout to the upside.
Showing 31 to 45 of 140 entries